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Abstract
Background: There has been a dramatic increase in the development of electronic systems to support cancer patients to report
and manage side effects of treatment from home. Systems vary in the features they offer to patients, which may affect how patients
engage with them and how they improve patient-centered outcomes.
Objective: This review aimed to (1) describe the features and functions of existing electronic symptom reporting systems (eg,
symptom monitoring, tailored self-management advice), and (2) explore which features may be associated with patient engagement
and patient-centered outcomes.
Methods: The review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and
followed guidelines from the Centre for Reviews and Dissemination (University of York, United Kingdom). Primary searches
were undertaken of MEDLINE, Embase, PsycInfo, Web of Science, Cochrane Central Register of Controlled Trials, and the
Health Technology Assessment databases. Secondary searches were undertaken by screening reference lists and citations. Two
researchers applied broad inclusion criteria to identify and select relevant records. Data were extracted and summarized using
Microsoft Excel. In order to meet the aims, the study selection, data extraction, and data synthesis comprised two stages: (1)
identifying and characterizing available systems and (2) summarizing data on patient engagement and patient-centered outcomes.
Results: We identified 77 publications relating to 41 distinct systems. In Stage 1, all publications were included (N=77). The
features identified that supported clinicians and care were facility for health professionals to remotely access and monitor
patient-reported data (24/41, 58%) and function to send alerts to health professionals for severe symptoms (17/41, 41%). Features
that supported patients were facility for patients to monitor/review their symptom reports over time (eg, graphs) (19/41, 46%),
general patient information about cancer treatment and side effects (17/41, 41%), tailored automated patient advice on symptom
management (12/41, 29%), feature for patients to communicate with the health care team (6/41, 15%), and a forum for patients
to communicate with one another (4/41, 10%). In Stage 2, only publications that included some data on patient engagement or
patient-centered outcomes were included (N=29). A lack of consistency between studies in how engagement was defined, measured,
or reported, and a wide range of methods chosen to evaluate systems meant that it was not possible to compare across studies or
make conclusions on relationships with system features.
Conclusions: Electronic systems have the potential to help patients manage side effects of cancer treatment, with some evidence
to suggest a positive effect on patient-centered outcomes. However, comparison across studies is difficult due to the wide range
of assessment tools used. There is a need to develop guidelines for assessing and reporting engagement with systems, and a set
of core outcomes for evaluation. We hope that this review will contribute to the field by introducing a taxonomy for characterizing
system features.
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Introduction
Increased efficacy of cancer treatments has led to a rising global
population of people living with and beyond cancer. Effective
multimodal cancer treatments can slow disease progression,
ease the symptoms of the disease, and in some cases cure disease
altogether. However, treatments can cause a vast array of side
effects such as nausea, pain, fatigue, and diarrhea, which may
negatively affect a patient’s quality of life (QoL) and may even
become life-threatening, with severe cases such as neutropenic
infections. Many cancer treatments are delivered in an
ambulatory setting and methods of follow-up and support are
highly variable dependent on disease, treatment type, and local
practice and resources. Information is commonly provided by
the health care team on expected and possible side effects, and
patients are advised to seek help if symptoms become a cause
for concern. However, patients may not always be able to fully
absorb this information at the time it is provided [1] or feel
confident in making decisions on when additional hospital
contact is necessary between routine clinical reviews [2].
Furthermore, clinicians are mainly reliant on interpreting patient
retrospective reports of treatment side effects to ensure safety
of care and manage supportive medications. Side effects are not
often documented in medical records in a consistent and
comparable way [3].
Over the past decade, there has been a dramatic increase in the
number of electronic systems developed to support patients
during and after cancer treatment by using patient-reported
outcome measures (PROMs) to remotely assess symptoms [4-8].
The routine use of PROMs in oncology care as a strategy to
enhance symptom monitoring has demonstrated many benefits,
such as improved communication between clinicians and
patients, and better symptom awareness [9]. Using electronic
systems to collect and manage PROMs data has the potential
to overcome some of the common challenges previously
associated with collating data collected on paper. More recently
developed systems can be accessed from any Web-enabled
device, allowing patients to report symptoms from home using
their own electronic devices such as computers, tablets, or
mobile phones. This can be done in real time, rather than relying
on retrospective reporting and potentially allows automated
documentation of patient reports in the medical record [10].
There is considerable variation in the features offered by
symptom reporting systems. Some primarily focus on making
symptom data routinely available to health professionals and
provide alerts when severe symptoms have been reported
[5,11-15]. Others have been developed with a greater focus on
patient self-management, delivering tailored and automated
self-management advice when appropriate, and advising patients
to contact their health care team when necessary [8,16-20].
Some systems use a combination of both approaches [4] and
can also include additional features such as facilitating
communication with medical teams or other patients.
The availability or absence of certain features may affect how
patients engage with systems [21,22]. The terms “engagement”
and “adherence” are often used interchangeably in this context.
However, adherence suggests an optimal way to use a
technology and this is not always easy to define [23]. For the
purposes of this review, we refer to engagement in a broad sense
of levels of patient usage of the technology. Understanding the
key components that can enhance patient engagement with
electronic symptom reporting is potentially crucial for improving
the development of future systems and encouraging their
implementation into standard practice. There are many factors
that are likely to have an impact, from individual differences
[24], socioeconomic status and healthy literacy [25], to basic
system usability [21,26]. There is relatively little currently
known about the underlying processes and particularly the role
that the availability of systems features might play. However,
there is evidence to suggest that individuals vary in the features
that they value and use most [20]. In addition, needs may change
over time, as patients become more experienced with the system,
but also with their disease and treatment [27].
The presence or absence of system features is also likely to
affect the level of patient benefit gained from using the system.
For example, changes in behavior or disease outcome have been
more often observed with interactive interventions in comparison
with those that are purely educational [28]. While the use of
interactive online systems is associated with greater
self-efficacy, better self-management, and more participation
in health care [29-32], this may be associated only with specific
features such as interactive communication and progress tracking
features [33], and consultation and self-management support
[34].
Systematic reviews traditionally focus on high-quality evidence
for a specific research question. However, increasingly, the
value of taking a broader approach to inclusion is being
recognized as important to answer complex research questions,
particularly in the emerging field of online health interventions
[35,36]. With this in mind, the focus of this review was to take
an inclusive approach to systematically review and describe the
features and functions of existing systems. We also wanted to
focus on understanding the level of evidence indicating whether
key system features are associated with better patient system
engagement and patient-centered outcomes.
The aims of this systematic review are to (1) describe the
features and functions of existing electronic symptom reporting
systems developed for patients during cancer treatment, and (2)
explore which features of these systems may be associated with
patient engagement and outcomes. Specifically, we wanted to
summarize (1) patient engagement and whether this is related
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to specific system features (eg, symptom monitoring, tailored
self-management advice), and (2) patient-centered outcomes
used to evaluate systems and whether better outcomes are
associated with specific features.
Methods
Protocol and Registration
Details of the protocol were registered on the International
Prospective Register of Systematic Reviews (PROSPERO)
database [37]. There were no major deviations from the protocol.
However, study selection, data extraction, and data synthesis
comprised two stages: (1) identifying and characterizing
available systems, and (2) summarizing data on patient
engagement and patient-centered outcomes. This staged
approach was not initially planned but was necessary in order
to meet the aims of the review.
Eligibility Criteria
The review question was refined using Population, Intervention,
Comparator, Outcomes, Study design (PICOS) criteria (Table
1), and eligibility criteria were developed based on this. For
Stage 1, we wanted an overview of all systems available, so all
relevant publications including published abstracts, protocols,
and qualitative studies were included. However, discussion
papers or systematic reviews were excluded. For Stage 2, in
order to review evidence available on patient engagement and
any patient-centered outcomes, we wanted to include feasibility
studies with any evaluation data of patient use, rather than
restricting criteria to randomized controlled trials (RCTs) only.
Only full papers were included in this stage. Criteria were
piloted by 2 researchers (LW and KA) on a subset of 10
randomly selected papers and subsequently refined and clarified
before the next stage.
Information Sources
Studies were identified from systematic searches of Medline,
Embase, PsycInfo, Web of Science, Cochrane Central Register
of Controlled Trials, and the Health Technology Assessment
databases in March 2016. Due to the nature of the review, results
were limited to those published after 2000. No restrictions were
imposed on language of publication. Searches were updated on
September 12, 2017. Reference lists of relevant publications
were screened to identify papers not picked up by the electronic
searches. In addition, citations of selected key papers were
searched.
Search Strategy
A detailed example of the search strategy used for Medline is
outlined in Textbox 1. This search strategy was adapted for each
of the databases.
Study Selection
For initial screening, a decision for inclusion was made based
on title and where available, abstract. This was carried out by
one researcher (LW) only, and for this reason, a cautious
approach erring on the side of over-inclusion was used.
Following this, 2 researchers (LW and KA) independently
assessed all remaining papers for relevance. Disagreements
were resolved by consensus after referring to the protocol. All
discussions and decision making were documented. Where there
was insufficient information to make a decision, authors were
contacted for further information. If no response was received
within 2 weeks, a final decision was made based on available
information.
Table 1. PICOS (Population, Intervention, Comparator, Outcomes, Study) criteria.
CriteriaCategory
Male and female adults >18, no upper age limit, worldwide with any cancer diagnosis, receiving cancer treatment OR within 3 months
of completing treatment. The cancer treatment to include any treatment with significant side effects (eg, systemic therapies, radiother-
apy, biological therapies).
Population
Online systems for patients to report or manage symptoms and side effects during cancer treatment from home; Internet-based or -enabled
systems, including mobile apps. Other forms of interactive health communication applications, eg DVDs, games were excluded.
Purely educational systems not interactive in any way were excluded. Systems developed to assess and monitor purely psychosocial
symptoms were excluded (eg, depression, anxiety, emotional coping or stress). Sleep and fatigue were included. Systems designed to
be accessed at one time point only were excluded; access to the system had to be ongoing.
Intervention
Stage 2 only: The review included studies with any comparator (eg, randomized or nonrandomized studies), in addition to studies with
no comparator (eg, feasibility studies).
Comparator
Stage 1: Dependent on the nature and number of papers found, we aimed to characterize systems. For example, we identified if studies
included features such as Monitoring of symptoms by health care professionals (HCPs), Alerts for severe symptoms sent to HCPs,
Monitoring of symptoms by patients (eg, graphical or tabular), Automated feedback/advice based on responses, Access to symptom
information, Communication with other cancer patients, Direct communication with HCPs (distinct from symptom monitoring by
HCPs).
Stage 2: We aimed to collect where available, information on engagement with systems and information on any patient-centered outcomes,
including but not restricted to any QoL measures; self-efficacy measures including patient activation, patient empowerment, mastery;
and patient satisfaction.
Outcomes
Stage 2 only: The review was not restricted to randomized controlled trials, and feasibility studies with any evaluation data were in-
cluded. Patients had to be using the system over time, and there had to be at least one intended time point of use more than 3 weeks
after baseline. This timeframe was selected as many standard chemotherapy treatments are administered every 3 weeks.
Study design
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Textbox 1. Example of search strategy used (Ovid Medline).
1. Neoplasms/
2. oncolog*.mp.
3. cancer patient*.mp.
4. 1 or 2 or 3
5. Medical Informatics/
6. Telemedicine/
7. Mobile Applications/
8. Smartphone/
9. Self Report/
10. Self Care/
11. Self-Assessment/
12. (electronic adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or Self-manage* or Self monitor* or Self-monitor*
or Symptom report* or Symptom-report* or Symptom manage* or Symptom-manage*)).mp.
13. (online adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or Self-manage* or Self monitor* or Self-monitor*
or Symptom report* or Symptom-report* or Symptom manage* or Symptom-manage*)).mp.
14. (web* adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or Self-manage* or Self monitor* or Self-monitor*
or Symptom report* or Symptom-report* or Symptom manage* or Symptom-manage*)).mp.
15. (remote* adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or Self-manage* or Self monitor* or Self-monitor*
or Symptom report* or Symptom-report* or Symptom manage* or Symptom-manage*)).mp.
16. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. 4 and 16
Limit 17 to (humans and yr=“2000 -Current”)
Data Items
For Stage 1, basic data were extracted on authors, title, year of
publication, and country of origin, in addition to the name (if
any given) and type of system being described (eg, Web-based
or mobile app). If the system did not already have a descriptive
name, an arbitrary name was assigned (eg, System A). A
preliminary list of common features was created based on
existing knowledge and further developed throughout data
extraction until a comprehensive list of common or important
features was identified. Data were extracted from each
publication on the presence of each feature. This was coded as
“Yes” only if it was explicitly described in the publication,
otherwise it was coded as a “#” For abstracts, if it was unclear
whether or not a feature was present by information available
in an abstract, this was classed as “Unable to determine.” Where
information was lacking, authors were not contacted for
information. However, searches were undertaken for other
publications related to the same system.
For Stage 2, data were extracted from studies with some form
of system evaluation (eg, patient use of system or evaluation of
efficacy). This included data on the number of patient
participants, baseline demographics, disease and treatment type,
duration of the evaluation, methods used to assess engagement,
and actual usage or adherence. Where available, data were also
extracted on any patient-centered outcomes used and results of
evaluation.
Data Extraction
Data were extracted using the online Systematic Review Data
Repository [38]. The form was piloted on 10 randomly selected
papers and further refined. For Stage 1, three additional
researchers (KA, BC, MA) each double-coded a number of
allocated publications, totaling 36% (27/77) of the overall
included publications. A high level of agreement (86%) was
found. Discrepancies were resolved by referring back to the
protocol and additional publications where available. For Stage
2, the same 3 researchers again each double-coded a proportion
of the included publications totaling 46% (13/29) and 100%
agreement was found.
Quality Assessment
Quality was assessed using the Downs and Black checklist for
nonrandomized studies [39] and was undertaken alongside data
extraction. It was deemed appropriate to assess only studies that
included some feasibility/evaluation data, that is, publications
included in Stage 2. Studies were given a score along a possible
range of 0-26.
Synthesis of Results
A narrative synthesis was undertaken using the guidelines
outlined by the Economic and Social Research Council [40].
Microsoft Excel was used to manage data. For Stage 1,
information from multiple publications relating to the same
systems was pooled to form a description of features. Where
information was conflicting due to earlier and later iterations,
the most recent description was used. For Stage 2, information
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was collected on how patient engagement was assessed for any
feasibility study or trial that included these data. For trial studies,
information was collected on primary and secondary study
outcomes and any results recorded. We then summarized these
data to explore any relationships with system features identified
in Stage 1.
Results
Study Selection
An overview of search and selection procedures is outlined in
Figure 1. A total of 6727 publications were identified after
removal of duplicate publications, including two publications
identified from secondary searches (ie, citation and reference
lists). All publications were in English. We assessed 279
publications for eligibility, and a total of 202 papers were
excluded at this point based on predefined eligibility criteria
(intervention, eg, not home-based or Web-based, n=132;
population, eg, patients not on active treatment, n=41; discussion
paper or systematic review, n=19; or abstract unavailable, n=10).
We included 77 publications in Stage 1 of the review (ie,
systems descriptions). A large proportion (23/77, 30%) of these
publications were abstracts. The reasons for exclusions are
outlined in Figure 1. Those 8 publications categorized under
“Other” included 2 summary papers giving an overview of
development and evidence for a system, a description of standard
usability testing, a cost-effectiveness analysis, a content analysis
of email communication within a system, a discussion of design
approaches and methodology, an evaluation focusing on blood
monitoring, and one publication where we were not able to
access the full paper and did not receive a response from the
authors when this was requested. We identified 29 publications
for inclusion in Stage 2 of the review (ie, patient engagement
and evaluation of systems). These were 21 feasibility studies
and 8 controlled trials (7 randomized and 1 nonrandomized).
Stage 1: Description of Systems and Features
The 77 publications referred to 41 individual systems. Most
originated from the United States (19/41, 46%) or the United
Kingdom (6/41, 15%), and all publications were available in
English. Systems were commonly Web-based (24/41, 56%),
27% (11/41) were mobile apps, 2 were both mobile and
Web-based (2/41, 5%), and 22% (9/41) were Web-enabled
mobile devices purposely designed for symptom reporting and
were provided to patients for the duration of the study.
Figure 1. Summary of papers identified and subsequently excluded/included in this review.
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Seven common system features were identified. Figure 2
outlines each of the features and its prevalence in the 41
identified systems. Features could be categorized broadly as
supporting patients to monitor and manage their own symptoms,
and to communicate with health professionals and one another,
or supporting clinicians to monitor and manage patient
symptoms.
Table 2 [4-8,11-20,41-102] provides an overview of each
identified system and its associated publications, in addition to
the presence or absence of each of the features identified in
Figure 2.
Stage 2: Patient Engagement and Evaluation
Quality Assessment
Along a possible range of 0-26, the overall median quality
assessment score of studies using the Downs and Black checklist
was 17.0 (mean 16.2, SD 5.3, range 2-24). For trials described
in the section on patient-centered outcomes
[5,6,8,49,60,79,88,100], the median score was higher at 20.0
(mean 20.4, SD 2.6, range 17-24).
Patient Engagement
Table 3 [5,6,8,11-15,42,43,49,60,63,65,68,73-75,79,81,82,84,87,
88,90,92,93,100,101] summarizes data on patient engagement
from the 29 included studies (ie, 21 feasibility studies, 7 RCTs,
and one non-RCT [88]). All 21 feasibility studies (100%)
reported some data on patient engagement, although there was
variation in how engagement was defined and measured. Three
of the eight trials (38%) did not report any data on patient
engagement [6,79,100].
Of the 29 studies, the most common method of assessing
engagement was the number of symptom report completions or
number of times the system was accessed (12/29, 41%)
[15,49,60,63,65,68,74,87,88,90,92]. This was given as an overall
figure for the whole sample [15,49,68,90,92], as an average per
patient [13,15,65,74,90], or with a breakdown of the variance
[63,87]. Nine studies (9/29, 31%) assessed adherence by number
of actual completions/accesses in comparison to the number of
expected completions/accesses [5,13,14,73,75,81,84,93,101].
This was reported as median or mean adherence of the overall
sample for the duration of the study period [2,73,75,81,93,101],
or with a breakdown of adherence at different time points
[14,84]. Only 2 studies studies (2/29, 7%) categorized patients
as users or nonusers dependent on predefined criteria [11,12].
Four studies (4/29, 14%) combined results of patients reporting
from home and in clinic [11,13-15]. Not all studies reported on
actual usage, and some used evaluation questionnaires with or
without semistructured interviews to assess acceptability to
patients [42,43,65,82].
Due to the variation in the methods of reporting, it was not
possible to determine if there was any overall association
between engagement and specific system features.
Figure 2. Overall summary of prevalence of identified system features.
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Table 2. Identified systems with description of features and associated publicationsa.
Included a fo-
rum for pa-
tients to com-
municate with
one another
Included a fea-
ture for pa-
tients to com-
municate with
the health care
team
Provided gen-
eral patient in-
fo about can-
cer treatment
and side ef-
fects
Provided tai-
lored automat-
ed patient ad-
vice on manag-
ing symptoms
Included a
function to
send alerts to
health profes-
sional for se-
vere symp-
toms
Allowed pa-
tients to moni-
tor their symp-
tom reports
over time (eg,
graphs)
Allowed
health profes-
sional to re-
motely access
and monitor
patient report-
ed data
Publication
type (with rele-
vant refer-
ences)
System name
(country)and
type
xxx✓✓x✓Randomized
trial [6], Sec-
ASyMs (UK)
Mobile device
ondary analy-
sis of RCTb
[41], Feasibili-
ty studies
[42,43], Ab-
stracts
[44-47], Other
[48]
✓x✓xx✓xRandomized
trial [49]
CASSY
(USA)
Web-based
–––––––Abstract [50]CHES (Aus-
tria)
Web-based
–––––––Other [51]COPE-CIPN
(USA)
Web-based
xx✓✓x✓xDevelopment
paper [52],
Protocol [53]
CORA (USA)
Mobile app
xx✓✓✓✓✓Protocol [4],
Abstracts
[54-59]
eRAPID (UK)
Web-based
xx✓✓✓✓✓Protocol [7]eSMART
(UK)
Mobile device
xxx✓x✓xRandomized
trial [60], Sec-
ESRA-C
(USA)
Web-based ondary analy-
sis of RCT
[61], Qualita-
tive paper [62]
xx✓xx✓xFeasibility
study [63],
Healthweaver
(USA)
Web-based &
mobile app
Development
paper [64]
xx✓✓✓x✓Feasibility
study [65]
HSM (UK)
Mobile device
––––––✓Abstract [66]ICT-FP7
(France)
Mobile device
xx✓✓✓✓✓Protocol [67]INTERAK-
TOR (Swe-
den)
Web-based &
Mobile app
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Included a fo-
rum for pa-
tients to com-
municate with
one another
Included a fea-
ture for pa-
tients to com-
municate with
the health care
team
Provided gen-
eral patient in-
fo about can-
cer treatment
and side ef-
fects
Provided tai-
lored automat-
ed patient ad-
vice on manag-
ing symptoms
Included a
function to
send alerts to
health profes-
sional for se-
vere symp-
toms
Allowed pa-
tients to moni-
tor their symp-
tom reports
over time (eg,
graphs)
Allowed
health profes-
sional to re-
motely access
and monitor
patient report-
ed data
Publication
type (with rele-
vant refer-
ences)
System name
(country)and
type
x✓xxxx✓Feasibility
study [68]
KAIKU (Fin-
land)
Web-based
✓>––––––Abstract [69]MADELINE
(USA)
Mobile app
–––––––Abstract [70]MSKCC Web-
Core (USA)
Web-based
x✓x✓✓✓✓Development
paper [71],
Protocol [72]
Onco-TREC
(Italy)
Mobile app
xxxx✓✓✓Feasibility
study [73]
PatientView-
point (USA)
Web-based
xxxxxx✓Feasibility
study [74]
PaTOS (USA)
Web-based
xxxxxx✓Feasibility
study [75]
Pit-a-pit (Ko-
rea)
Mobile app
xx✓✓✓✓✓Protocol [76],
Abstract [77]
PRISMS
(Australia)
Mobile device
–––––✓✓Abstract [78]PROCDIM
(USA)
Web-based
xxxx✓x✓Randomized
trial [79], Oth-
er [80]
QoC Health
Inc (Canada)
Mobile app
xxxx✓xxFeasibility
study [81]
RemeCoach
(Belgium)
Mobile device
x✓✓xxx✓Feasibility
study [82],
Other [83]
SCMS (Singa-
pore)
Web-based
xxx✓✓✓xRandomized
trial [5], Feasi-
bility studies
[11-15,84]
STAR (USA)
Web-based
xxx✓✓x✓Development
paper [85]
The Health
Buddy (R)
(USA)
Mobile device
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Included a fo-
rum for pa-
tients to com-
municate with
one another
Included a fea-
ture for pa-
tients to com-
municate with
the health care
team
Provided gen-
eral patient in-
fo about can-
cer treatment
and side ef-
fects
Provided tai-
lored automat-
ed patient ad-
vice on manag-
ing symptoms
Included a
function to
send alerts to
health profes-
sional for se-
vere symp-
toms
Allowed pa-
tients to moni-
tor their symp-
tom reports
over time (eg,
graphs)
Allowed
health profes-
sional to re-
motely access
and monitor
patient report-
ed data
Publication
type (with rele-
vant refer-
ences)
System name
(country)and
type
✓✓✓✓x✓xRandomized
trial [8], Sec-
ondary analy-
sis of RCT
[17,18], Quali-
tative paper
[20], Other
[16,19]
WebChoice
(Norway)
Web-based
–––✓––✓Abstract [86]WRITE
(USA)
Web-based
xxxx✓xxFeasibility
study [87]
System A
(USA)
Web-based
✓✓✓x✓✓✓Nonrandom-
ized trial [88],
Development
paper [89],
Feasibility
study [90]
System B (The
Netherlands)
Web-based
–––––––Other [91]System C
(USA)
Web-based
xx✓✓✓✓✓Feasibility
study [92]
System D
(Sweden)
Mobile app
xxx✓✓✓✓Feasibility
study [93]
System E
(UK)
Mobile device
–✓–✓–✓–Abstract
[94,95]
System F
(Canada)
Web-based
–––✓–✓–Abstract [96]System G
(Denmark)
Web-based
xxxx✓x✓Other [97]System H
(UK)
Mobile device
–––––––Abstract [98]System I
(USA)
Web-based
––––––✓Abstract [99]System J
(USA)
Web-based
xxxxx✓✓Randomized
trial [100]
System K
(Switzerland)
Mobile app
xxxxxx✓Feasibility
study [101]
System L
(USA)
Mobile app
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Included a fo-
rum for pa-
tients to com-
municate with
one another
Included a fea-
ture for pa-
tients to com-
municate with
the health care
team
Provided gen-
eral patient in-
fo about can-
cer treatment
and side ef-
fects
Provided tai-
lored automat-
ed patient ad-
vice on manag-
ing symptoms
Included a
function to
send alerts to
health profes-
sional for se-
vere symp-
toms
Allowed pa-
tients to moni-
tor their symp-
tom reports
over time (eg,
graphs)
Allowed
health profes-
sional to re-
motely access
and monitor
patient report-
ed data
Publication
type (with rele-
vant refer-
ences)
System name
(country)and
type
–––––––Abstract [102]System M
(USA)
Mobile app
a“✓” denotes feature is present, “x” denotes feature is not present, and “–“ denotes that it was not possible to determine whether feature was present or
not.
bRCT: randomized controlled trial.
Patient-Centered Outcomes
All the trials used some measure of patient-centered outcome
to evaluate system efficacy, most commonly validated QoL and
symptom and psychosocial outcome measures. Table 4 outlines
each trial [5,6,8,49,60,79,88,100], the intervention and
comparator groups, outcomes reported, and a summary of the
results.
Global Quality of Life
CASSY [49] and STAR [5] interventions both demonstrated
improvements in overall QoL. However, in addition to the online
component, CASSY included access to a collaborative care
coordinator with experience in cognitive behavioral therapy and
psycho-oncology, which is likely to have contributed to the
efficacy. In the STAR study, patients were allocated to
computer-experienced and inexperienced groups prior to
randomization and only the computer-experienced group had
access to the system from home. Results are pooled, making it
difficult to assess efficacy for our purposes. No significant
impact on QoL was found for WebChoice [8].
Physical Symptoms
An overall reduction of symptom distress was found in the
studies assessing Electronic Self-Report Assessment-Cancer
(ESRA-C) [60] and WebChoice [8]. However, in addition to
the online intervention, ESRA-C also included a communication
coaching component to improve symptom disclosure to
physicians. System B [88] was found to have significant positive
impact on the general physical complaints subscale compared
to the control group.
Advanced Symptom Management System (ASyMs) [6] and
Comprehensive Electronic Cancer Support System for the
Treatment of Cancer Related Symptoms (CaSSY) [49] both
demonstrated positive impact on levels of fatigue while System
K [100] demonstrated a lesser decline in functional activity in
contrast to the control group, but this was not significant. Both
ASyMs and System K were evaluated using the same measure
as used to assess symptoms in the intervention, which may have
affected results.
Self-Efficacy
WebChoice [8] and System B [88] both demonstrated a positive
impact on self-efficacy. However, for System B, this was
assessed only as a subscale of a main measure. System K [100]
reported an improvement in patient empowerment; however,
this was assessed using a single item regarding using the Internet
for information seeking, which is unlikely to be a reliable
measure.
Other Psychosocial Outcomes
CASSY [49] and WebChoice [8] demonstrated significant
reductions in depression in intervention compared to control
groups. System B [88] demonstrated no difference on the
depression subscale of a QoL measure but a significant impact
on state anxiety and fear related to specific head and neck
problems. WebChoice demonstrated no impact on social support
[8]. QoC Health Inc [79] was primarily assessed on number of
hospital contacts but also included patient scores of convenience
and satisfaction using a simple 5-point Likert scale and found
an impact for convenience, but not for patient satisfaction.
Due to the considerable variation in outcomes used and study
design, it was not possible to assess any relationships between
outcomes and system features.
J Med Internet Res 2019 | vol. 21 | iss. 1 | e10875 | p.10http://www.jmir.org/2019/1/e10875/
(page number not for citation purposes)
Warrington et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 3. Overview of patient engagement data.
Brief summary of findingsMethod of evaluation/ patient
engagement
System name, patient group (patients, N), treatment type
and study duration, quality assessment score (QAS)
Feasibility studies (n=21)
Actual usage not reportedEvaluation questionnaire and
semistructured interviews
ASyMS-R [42], Lung (N=16)
During and 1 month after thoracic radiotherapy
QAS=19
Patients perceived it to positively impact on care and
promote timely reporting and management of symp-
toms
Actual usage not reportedEvaluation questionnaireASyMS [43], Colorectal or lung (N=18)
During 2 cycles of chemo
QAS=15
Patients reported it helped monitor symptoms, promote
self-care, and improve symptom management
All patients used website at least 3x/week, 7 patients
used it almost daily
# of completions/ accessesHealthWeaver [63], Breast (N=9)
Undergoing active treatment, 4 weeks
QAS=8 Phone component used almost daily by 5 patients,
3x/week by 1 patient, and 1-2x/week by 3 patients
All patients completed 1-34 symptom reports, average
14 overall (SD 10.2)
# of completions/ accesses and
evaluation questionnaires
HSM [65], Lung or colorectal (N=18)
During 2 cycles of chemo
QAS=10 High variation in use of self-management advice
Patients found system easier to use and more useful
than expected
514 symptoms reported (including zero grades)# of completions/ accessesKaiku [68], Head & neck (N=5)
Radiotherapy, during and 1 month after
QAS=12
23 questionnaires completed
38 messages sent
190/224 symptom reports completed (85%)# of accesses/ expected accessesPatientViewpoint [73], Breast or prostate (N=47)
Medical oncology treatment
UTD - 3 onsite visits (not specified)
QAS=15
Median expected questionnaires completed by individ-
ual patients was 71%
Majority of questionnaires completed offsite (n=160;
87%)
28/30 patients observed for 10 weeks# of completions/ accessesPaTOS [74], Any disease site (N=30)
Chemo, 10 weeks
QAS=6
Total 231 accesses, 193 fully completed
Total of 1870 symptoms observations (average 69 per
patient, 1.5 per day)
1215/2700 responses (compliance=45.0 %)# of accesses/ expected accessesPit-a-pit [75], Breast (N=30)
Neo-adjuvant chemo, 90 days
QAS=14
Median patient-level reporting rate was 41.1% (range
6.7-95.6%)
Average daily compliance 91.2%# of accesses/ expected accessesRemeCoach [81], Advanced solid tumors, eg, colorec-
tal, gastric-esophageal, and pancreatic adenocarcinoma
(N=11)
Duration of Teysuno treatment
QAS=18
Could not determine longitudinal compliance because
of the low patient number using the coach for an ac-
ceptable duration of time
All patients completed at least 1 symptom reportEvaluation questionnaireSCMS [82], Breast, lung, or colorectal (N=4)
During 4 cycles of chemo
QAS=10
Questionnaire revealed patients found system useful
and easy to use
Compliance of patients gradually decreased# of accesses/ expected accessesSTAR [84], Gynecologic malignancy (N=49)
Laparotomy, 6 weeks
QAS=20
92% of patients completed preoperative session, and
74% completed Week 6 session
Majority of patients (82%) completed at least 4/7 total
sessions in STAR
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Brief summary of findingsMethod of evaluation/ patient
engagement
System name, patient group (patients, N), treatment type
and study duration, quality assessment score (QAS)
Patients could access from home or in clinicUsers/nonusers (logged in/did
not log in)
STAR [11], Gynecologic malignancy (N=80)
Chemo, 8 weeks
QAS=16
25% used only in clinic waiting area, remainder logged
in from home and clinic
Most patients with home computers (83%) logged in
from home without reminders
Patients could access from home or clinicUsers/nonusers (logged in/did
not log in)
STAR [12], Not specified (N=180)
Chemo, 8 weeks
QAS=8
2/3 voluntarily logged in from home computers without
prompting
Patients could access from home or clinic# of accesses/ expected accessesSTAR [13], Thoracic malignancies (N=107)
Chemo, 16 months
QAS=20
16 patients (15%) accessed system from home
Home users accessed system more frequently than
those using in clinic (avg=23 sessions, range 3-144)
vs (avg=9, range 1-36) respectively
Patients could access from home or in clinic# of completions/ accessesSTAR [15], Lung, gynecologic, breast, genitourinary
(N=286)
Duration of chemo
QAS=19
Total 8690 logins (median 17 logins per patient), avg
0.9 logins per patient per week
71% from home and 29% from clinic
74% (n=71) completed at least 4/7 surveys and were
considered responders
# of accesses/ expected accessesSTAR [14], Gynecologic malignancy (N=96)
Laparotomy, preoperatively & weekly 6-wks postla-
parotomy
QAS=17
63% (n=69) completed preoperative session. Remain-
ing completed subsequent surveys.
9 (9%) patients completed only 1 survey
65% (13/20) completed 8 symptom assessments# of completions/ accessesSystem A [87], Hepatobiliary and GI (N=20)
Preoperatively and 2 weeks after discharge for curative
resection
QAS=17
75% (15/20) completed 4 QoL assessments
Mean 7 minutes to complete MD Anderson Symptom
Inventory and mean 4 minutes to complete EuroQoL-
5D-5L
All patients used system (total sessions=982)# of completions/ accessesSystem B [90], Head and neck cancer (N=36)
Surgery, 6 weeks
QAS=17
Avg no of sessions was 27.3 (SD 18.4, range 4-69)
Avg session 12 minutes, longest session 1 hour 38
minutes
Patients reported for mean of 10 days# of completions/ accessesSystem D [92], Prostate (N=9)
Radiation, 2 weeks
QAS=13
Estimated time for report 5 minutes
Self-care advice accessed by 85%, who logged 20
views at 34 symptoms
59 alerts: 55 yellow and 4 red
Data entry compliance was excellent (98% of the
twice-daily input was complete) from all 6 patients
with the exception of one question
# of accesses / expected accessesSystem E [93], Colon (N=6)
Complete resection, during 2 cycles of chemo
QAS=11
Median compliance 71% (interquartile range [IQR],
45%-80%)
# of accesses/ expected accessesSystem L [101], Head and neck (N=22)
Duration of radiation (approx. 5-7 weeks)
QAS=16 6 patients (27%) compliance ≥80%, 2 patients (9%)
100% compliant
Median reports submitted 34 (IQR 21-53)
Randomized controlled trials (RCTs; n=7; n refers to # of patients expected to use the system [ie, intervention arm])
Not reportedNot reportedASyMS [6], Breast, lung, or colorectal (N=56)
4 cycles of chemo
QAS=22
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Brief summary of findingsMethod of evaluation/ patient
engagement
System name, patient group (patients, N), treatment type
and study duration, quality assessment score (QAS)
Total number of page views=1491# of completions/ accessesCASSY [49], Any cancer diagnosis (N=144)
Chemo, radiation, or surgery, 6 months
QAS=19
Total duration in minutes=1813.9
Total views and duration given for individual patients
Median access rate of 4 (range 2-4) at study time points# of completions/ accessesESRA-C [60], Diagnosis of cancer (N=374)
Any therapeutic regimen, UTD, over 4 visits
QAS=24
Median access rates of 1 (range 0-8) at voluntary times
Not reportedNot reportedQoC Health Inc [79], Breast (N=32)
Reconstructive surgery, 30 days
QAS=23
Computer experienced (home access) and inexperi-
enced (clinic access) figures combined
# of accesses/ expected accessesSTAR [5], Metastatic breast, genitourinary, gynecolog-
ic, or lung (N=286)
Duration of chemo
QAS=20
Avg 73% completed a self-report at any given clinic
visit (includes clinic completions)
77% logged on at least once# of completions/ accessesWebChoice [8], Breast or prostate (N=162)
Surgery plus radiation, chemo, hormone therapy, or a
combination, 1 year
QAS=23
23% never logged on
Of 103 (64%) who logged on more than once, avg lo-
gons=60 times (range 2-892)
Not reportedNot reportedSystem K [100], Breast cancer (N=95)
Adjuvant or neo-adjuvant chemo, 6 weeks
QAS=18
Non-RCT (n=1) (n refers to # of patients expected to use the system [ie, intervention arm])
Avg # of sessions=27, avg length of session=12 mins# of completions/ accessesSystem B [88], Head and neck cancer (N=39)
Surgery, 6 weeks
QAS=17
Avg # of completions=12.6
Avg # of messages=4.5
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Table 4. Overview of patient-centered outcomes data.
Summary of resultsOutcomes reportedIntervention and comparator groupsStudy, population (N); study
design
Higher reports of fatigue
(P=.04) and lower reports of
Primary outcomes: Paper
version of online question-
naire; Comparison between
Intervention (N=56):
Asked to complete a symptom questionnaire integrating
Common Toxicity Criteria Adverse Events (CTCAE)
ASyMs [6], Breast, lung, or
colorectal (N=112); 2-arm
randomized controlled trial
(RCT), 4 cycles of chemo
hand-foot syndrome (P=.03)
in control group compared
with intervention group
groups on mean scores from
4 paper-based completions
at baseline and before each
chemo cycle
grading system and Chemotherapy Symptom Assessment
Scale
Symptom information sent in real time to the study server
Patients receive severity dependent tailored self-care advice
on mobile phone interface
Evidence-based risk assessment tool alerts clinicians via a
dedicated 24-h pager system of any severe symptoms
Comparator (N=56):
Standard care following local guidelines and procedures
related to monitoring and reporting of chemo-related toxi-
No difference on nausea,
vomiting, diarrhea, or sore
mouth/throat
city including written and verbal information from nurses
administering chemo
Reductions of fatigue at 6
months (P=.09)
Primary outcomes: Depres-
sion (Centre for Epidemio-
logic Studies-Depres-
Intervention (N=144):
Access to psycho-educational website where patients could
record and monitor symptoms via graphs and journal
Access chat room to communicate with other study patients
Audiovisual and resource library including relaxation
techniques and educational videos
Phone contact (approx. every 2 weeks) with a collaborative
care coordinator with training and experience with cogni-
tive-behavioral therapy and psycho-oncology
Comparator (N=117):
Usual care provided by medical team plus assessment of
symptoms and blood draws at the same time as intervention
patients to evaluate efficacy of intervention
CASSY [49], Any diagnosis
of cancer
Chemo, radiation, or surgery
(N=261)
2-arm RCT, 6 months
Statistically and clinically
significant changes in over-
all QoL (P=.05)
sion≥16), Pain Brief Pain
Inventory, Anemia (Func-
tional Assessment of Cancer
Therapy [FACT]-Anemia),
Hepatobiliary (FACT-Hep)
Reductions in pain and de-
pression
Medium effect size for NK
cell number (Phi=0.491) at
6 months (chi-square=3.62,
P=.057)
Secondary outcomes: Serum
cytokines levels and Natural
Killer Cell (NK), Compari-
son at 6 months follow-up
Intervention had lower
symptom distress; mean
Primary outcomes: Symp-
tom Distress Scale (SDS)
Intervention (N=374):
Participants completed cancer symptoms and QoL (SxQoL)
assessments at each study time point and ad lib between
visits
Summary reports delivered to clinicians
Self-management advice given for 3 symptoms
Coaching to verbalize issues to health care team
Alert to contact health care team for severe symptoms
Patients could monitor symptoms via graphs and journal
Self-care strategies and coaching available at any time
Comparator (N=378):
Participants completed assessments at each study time point
Summary reports delivered to clinicians
Research staff verbally notified health care team of any
severe symptoms reported at clinic visit
Both groups were provided the same patient education
typically available in each clinic
ESRA-C [60], Diagnosis of
cancer
Any therapeutic regimen
(N=779)
2-arm RCT, UTD, over 4
visits
change in SDS-15 score was
1.27 ([SD], 6.7) in control
(higher distress) and -0.04
(SD 5.8) in intervention
(lower distress)
plus 2 items (impact on sex-
ual activity and interest,
fever/chills) to form SDS-
15, End point was change in
SDS-15 total score from
baseline to the end-of-study
time point SDS-15 score reduced by
estimated 1.21 (95% CI
0.23-2.20; P=.02) in inter-
vention vs control group
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Summary of resultsOutcomes reportedIntervention and comparator groupsStudy, population (N); study
design
Control group more likely
to attend in-person follow-
up care first 30 days after
surgery (95% CI 0.24-0.66;
P<.001)
Primary outcomes: Total
number of follow-up visits
(including specialists, family
physician, and emergency
department), Total number
of phone calls and emails to
health care team, Satisfac-
tion and convenience scores
using 5-point Likert scale,
Postop complications
Intervention (N=32):
Follow-up visits at 1 and 4 weeks replaced with examina-
tion of surgical site via photos submitted through mobile
app, plus completion of pain visual analog scale and quality
of recovery 9-item questionnaire
Reporting began after discharge from recovery room
Email reminder if submission not received
Surgeon used wireless interface to access data and monitor
patient’s condition
Severe scores flagged in the database for quick viewing.
Red flags prompted in-person follow-up
Physicians summarized data from mobile app using proto-
typical subjective, objective, assessment, and plan note at
1 or more time points during 30-day monitoring period
Comparator (N=33):
Patients in conventional follow-up group had planned
clinic follow-up at approx. 1 week and 4 weeks after oper-
ation
QoC Health Inc [79], Breast
cancer
Surgery (N=65)
2-arm RCT, 30 days
Intervention group sent
more emails than control
group (IRR 4.13; 95% CI
1.55-10.99; P=.005)
Intervention group reported
higher convenience scores
(IRR 1.39; 95% CI 1.09-
1.77; P=.008)
Combined results for com-
puter-experienced (home
system) & computer-inexpe-
rienced (clinic only) inter-
vention
Primary outcomes: EuroQol
EQ-5D Index given via pa-
per at clinic visits every 12
± 4 weeks throughout study
Intervention (N=286):
Remote access to Web-based interface including questions
adapted for patient use from CTCAE
Triggered email alerts to nurses when patient-reported
symptom worsened by 2 points or reached an absolute grade
Report tracking participant’s symptoms printed at each
clinic visit for both nurse and treating oncologist
No specific guidance provided to clinicians on actions to
take in response to alerts or printed symptom profiles
Comparators:
Intervention – Computer-inexperienced (N=155):
Similar to main intervention group but accessed system in
clinic only and did not have remote access
Computer-experienced – Usual care (N=253)
Computer-inexperienced – Usual care (N=72):
Usual care for the computer-experienced and computer-
inexperienced subgroups consisted of standard procedure
for monitoring and documenting symptoms
Symptoms discussed and documented in the medical record
during clinical encounters between patients and oncologists
Patients encouraged to initiate phone contact between visits
for concerning symptoms
STAR [5], Metastatic breast,
genitourinary, gynecologic,
or lung cancers (N=766)
Before randomization, partic-
ipants assigned to subgroups
(computer-experienced and
computer-inexperienced)
Only computer-experienced
intervention used system
from home
Duration of chemo
Greater improvement in
Health-Related QoL scores
in intervention vs usual care
arm (34% vs 18%) and
worsened among fewer
(38% vs 53%; P<.001)
Secondary outcomes: Sur-
vival at 1 year, Time to first
emergency room visit and
time to first hospitalization,
Time receiving active cancer
treatment, Number of nurs-
ing calls to patients
Greater survival in interven-
tion arm (69% vs 75%,
P=.05)
Fewer emergency room vis-
its in intervention (34% vs
41%, P=.02)
Intervention received chemo
for longer (8.2 vs 6.3
months, P=.002)
No difference in number of
nursing calls to patients
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Summary of resultsOutcomes reportedIntervention and comparator groupsStudy, population (N); study
design
Between-group differences
significant for the Global
Distress Index only (t=4.42;
P=.037)
Primary outcomes: Memori-
al Symptom Assessment
Scale Short Form
Intervention (N=162):
Assessment component to monitor and report symptoms,
problems, and priorities for support along physical, func-
tional, and psychosocial dimensions
Patients receive automated tailored self-management advice
based on responses
Patients receive advice to contact health care team when
appropriate
Info can be used to create a self-care plan
Info section with access to other reliable, relevant Web re-
sources
Communication section including (1) unrestricted support
forum for group discussion, allowing patients to post mes-
sages anonymously, (2) question-and-answer area where
patients can privately ask questions of expert nurses in
cancer care
Access to diary to keep personal notes
Comparator (N=163):
In addition to a letter giving their group assignment, partic-
ipants receive info sheet with suggestions for publicly
available, cancer-relevant websites
WebChoice [8], Breast or
prostate cancer
Surgery plus additional
treatment of either radiation,
chemo, hormone therapy, or
a combination of those)
(N=325)
2-arm RCT, 1 year
No significant differences
on the other subscales or to-
tal score or any secondary
outcomes
Secondary outcomes: Center
for Epidemiological Studies
Depression scale, Cancer
Behaviour Inventory, 15D
Health-related QoL, Medical
Outcome Study Social Sup-
port Survey
Experimental group showed
significant improvements in
depression (t=-2.71; P=.007)
Control group had worsened
self-efficacy (t=-2.82;
P=.005) and Health-related
QoL scores significantly
(t=-2.77; P=.006),
Intervention had significant-
ly better change from base-
line at 6 wks for state anxi-
ety (P=.01), fear related to
specific head and neck
problems (P=.02), physical
self-efficacy (P=.03), per-
ceived abilities in swallow-
ing and food intake (P=.04),
general physical complaints
(P=.02)
Primary outcomes: QoL
measure assessed state anxi-
ety, object anxiety, feelings
of depression, uncertainty,
feelings of insecurity, loss
of control, self-efficacy,
loneliness, and complaints
Intervention (N=39):
Provided with a laptop
Patients could be monitored at home (by means of electron-
ic questionnaires)
Could communicate (send messages) to team
Access to information
Communicate with fellow sufferers (via a forum)
Comparator (N=128):
Routine follow-up apps at 2 and 6 weeks after discharge
Patients could contact their care providers, both in- and
outside hospital, if considered necessary
System B, Van den Brink
[88]
Head and neck cancer
Surgery (N=163)
Nonrandomized trial, 6
weeks
Control groups showed
greater decline in functional
activity versus intervention
but not significant
Primary outcomes: Daily
functional activity measured
by ECOG
Intervention (N=49):
App and physician: Patients used mobile app and reviewed
reported data with treating physician at scheduled visits
Patients could report daily functional activity or symptoms
with indication of severity
Patients could edit a quick list of their preselected symp-
toms or select any of the 48 symptoms made available from
the CTCAE listing
Treating physician enabled access to review and discuss
electronically reported symptoms during scheduled visits
Comparators:
Attention-control group (N=46)
App only: Patients instructed to use the mobile app without
physician review
Control group (N=44):
Received regular physician support
System K, Egbring [100],
Breast cancer
Adjuvant or neo-adjuvant
chemo (N=139)
3 arm RCT, 6 weeks At last visit, intervention &
attention control patients re-
ported fewer concentration
issues than control group
(P=.002)
Secondary outcomes:
Symptom reporting (inter-
vention group and attention
control group only), Patient-
physician communication
(measure not specified), Pa-
tient Empowerment (mea-
sure not specified)
At third visit, significantly
more intervention & atten-
tion control patients con-
firmed use of Internet for
disease information com-
pared vs control
Discussion
Principal Findings
The main aim of this review was to systematically describe and
assess the features and functions of current systems available
for patients to report and manage side effects of cancer
treatment. We also wanted to focus on understanding the level
of evidence indicating whether key system features are
associated with better patient system engagement and patient
outcomes.
In Stage 1 of the review, we identified a total of 41 individual
systems. There was significant variation between systems,
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though published descriptions of systems were often limited.
We developed a taxonomy of features that were then classified
into those supporting clinicians to deliver patient care in an
innovative way and those aimed to support patients to better
self-manage their condition and identify when medical input
may be needed. This was successfully applied to describe the
presence or absence of common system features.
The review of features highlighted some interesting findings.
It was surprising to note that while over half (58%) of systems
had the facility for health care providers to monitor patient data
over time, fewer than half (46%) included the facility for patients
to monitor and review their own data. Given the available
evidence suggesting that self-monitoring is generally beneficial
to support patients’ self-management [28,33,103], this feature
could be very important to improve efficacy of systems and in
most cases, may be relatively easy to implement. Similarly, less
than half of the systems (41%) included a feature for delivering
advice to support patients to self-manage symptoms and less
than a third provided patients with access to general educational
information. The two least common features were facilities to
support communication between patients and health care
providers (15%) and communication between patients
themselves, respectively (10%). Previous research has indicated
that these features are highly valued and utilized by patients
[20,22,29,33]. It is likely that these features are less common
due to complexities in their implementation and maintenance.
For example, it may be difficult to engage busy clinicians to
respond to patient communication in this way, and there are
ethical considerations around the need to moderate patient
forums that are endorsed by a health care facility.
In Stage 2 of the review, we found little agreement on how
patient engagement with systems was defined, measured, or
reported, which meant it was not possible to compare levels of
engagement across studies or make any conclusions on
relationships with system features. Our review also indicated
heterogeneity in terms of outcomes used to evaluate systems.
Even of those that focused on symptoms or global QoL, the
variation in methods and measures used made meaningful
comparison impossible.
Due to the heterogeneous nature of reporting engagement and
outcomes, we were unable to explore any relationships with
system features. Our findings are similar to other reviews
undertaken in this area, which have also found that poor
assessment and reporting of patient engagement with systems
makes comparison between studies difficult. Brower et al made
quantifiable and comparable reports of engagement as part of
their inclusion criteria for their review, and results indicated
that facility for communication with other patients may be a
very influential factor in patient engagement and needs careful
consideration during system design [22]. However, other
oncology specific reviews have found that methods of assessing
and reporting patient engagement were too heterogeneous to
make meaningful conclusions [104,105]. We identified only 8
trials (7 randomized and 1 nonrandomized) that evaluated
systems, none of which reported any analysis on relationships
between engagement and outcomes, and 3 of which did not
report any data on patient engagement at all. This does not seem
to be unique to oncology. Donkin et al [106] set out to review
the impact of patient engagement with e-therapies across a range
of disease groups and similarly found that this is not a link that
is routinely explored.
Robust evidence supporting the value of systems for
patient-centered outcomes was limited, with a large proportion
of feasibility studies identified and even fewer RCTs. While all
trials used some measure of patient-centered outcome to evaluate
systems, a wide range of assessment tools were used, again
making comparison difficult. In addition, 2 studies used the
same measure for symptom assessment as part of the
intervention, as for the outcome measure. Only 3 trials reported
any measure of self-efficacy or patient empowerment, one of
which used a study-specific nonvalidated measure [79], and
another that was assessed using a subscale of a global QoL
measure [88]. There is an array of evidence to suggest that online
interventions can have a positive impact on self-efficacy and
patient activation levels [30,32,33,107]. Growing evidence
suggests that self-efficacy and patient activation play a
significant role in symptom management and quality of life
throughout cancer treatment [108,109] and are associated with
an array of improved health behaviors and health outcomes
[110-112] and lower use of hospital resources [113]. The
reviewed systems generally demonstrate positive outcomes for
patients as has been found in other reviews [31].
To our knowledge, this is the first systematic review in this field
to identify and characterize all available systems for patients to
report and manage side effects of cancer treatment, in addition
to evidence on patient engagement and patient-centered
outcomes.
Limitations
In order to meet the aims of the review, we included many
publications that provided limited information about the system
evaluated and some of which were of poor quality. However,
we felt that this was necessary in order to meet the aims of the
review and evaluate all evidence. Due to limitations on available
resources, the initial stage of study selection (ie, assessment of
titles and abstracts) was undertaken by a single reviewer. This
is a limitation of our methodology and may have resulted in
some bias of inclusion. To address this, a cautious approach
erring on the side of over-inclusion was adopted, in order for
records to be fully assessed by 2 researchers in the next stage
of the review.
Due to the heterogeneous nature of study designs and methods
of reporting engagement and outcomes, we were unable to
explore any relationships with system features. This is a field
of research that is still in its infancy, and the large number of
feasibility studies and abstracts identified are likely to be
indicative of this. The search was last updated September 2017.
Due to the fast-moving nature of this field of research, it is likely
that additional publications will be available by the time of
publication. This is a common limitation of systematic reviews
that is particularly pertinent with reviews of technology [114].
We did identify a number of protocols for planned quality trials
that may contribute to a more in-depth understanding of
associations between system features, adherence, and outcomes
in the future [4,7,53,67,72,76]. In addition, we have not explored
how issues with implementing systems into clinical practice
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may have affected the efficacy of systems. A discussion of these
issues is outside the scope of this review but has been
well-documented elsewhere [115].
Conclusions
There is a real need for evidence-based guidance on developing,
evaluating, and reporting systems. Based on this systematic
review, we propose a taxonomy for characterizing system
features to guide future development, improvement, and
implementation of such systems. More work is needed to
develop guidance for standardized reporting of patient
engagement both in feasibility studies, and in evaluation trials.
This is a complex and multifaceted issue, and it is important
that barriers and facilitators to engagement are shared to help
the evolution of more sustainable and valuable systems.
Similarly, the development of guidance for the evaluation of
systems is necessary. Variation in approaches to design and
implementation will rightly affect outcomes chosen to evaluate
efficacy [104,105]. However, there is enough commonality
between systems to call for a set of recommended core outcomes
to be developed [116]. More work is needed to develop this,
and this is something we will work towards in the future.
However, based on this review we recommend that all system
evaluations include (1) a description of the system using our
taxonomy of system features, (2) measures of feasibility and
engagement, (3) patient-centered outcomes focusing on QoL
and symptom improvement, in addition to those focusing on
self-efficacy and patient activation, and (4) a measure of health
economics. This will facilitate synthesis of evidence in order to
improve the design of systems and make them practically useful
for both patients and clinicians.
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